Tetsuhiko Shirasaka

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 819 citations

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

Tetsuhiko Shirasaka, K Nakano, T Takechi et al. · PubMed · 1996 · 370 citations

Nude Rats, Medicinal Chemistry, Oncology +13

Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

Tetsuhiko Shirasaka, Yuji Shimamoto, Masakazu Fukushima · PubMed · 1993 · 350 citations

Antitumor Activity, Gastrointestinal Pharmacology, Pathology +19

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

Kunihiko Tatsumi, Masakazu Fukushima, Tetsuhiko Shirasaka et al. · PubMed · 1987 · 261 citations

Pharmacotherapy, Experimental Pharmacology, Pharmaceutical Chemistry +20

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.

Keiji Hirata, N Horikoshi, K Aiba et al. · PubMed · 1999 · 227 citations

Medicinal Chemistry, Oncology, Health Sciences +15